DNA Biomarkers in Tissue Samples From Patients With Osteosarcoma
This trial is active, not recruiting.
|Treatments||dna methylation analysis, rna analysis, comparative genomic hybridization, gene expression analysis, microarray analysis, mutation analysis, laboratory biomarker analysis|
|Sponsor||Children's Oncology Group|
|Collaborator||National Cancer Institute (NCI)|
|Start date||August 2010|
|End date||January 2100|
|Trial size||200 participants|
|Trial identifier||NCT01190943, AOST10B5, COG-AOST10B5, NCI-2011-02840|
RATIONALE: Studying samples of tumor tissue and blood from patients with cancer in the laboratory may help doctors learn more about changes the occur in DNA and identify biomarkers related to cancer. DNA analysis of tumor tissue may also help doctors predict how well patients will respond to treatment.
PURPOSE: This research study is studying DNA biomarkers in tissue samples from patients with osteosarcoma.
Identification and validation of biomarkers with potential clinical utility
Male or female participants up to 120 years old.
DISEASE CHARACTERISTICS: - Diagnosis of osteosarcoma - Fresh-frozen samples collected at the time of diagnosis with matched blood DNA (preferred) from patients enrolled on the following osteosarcoma biology protocols: - COG-P9851 - COG-AOST06B1 - Available clinical outcome data PATIENT CHARACTERISTICS: - Not specified PRIOR CONCURRENT THERAPY: - Not specified
|Official title||Therapeutically Applicable Research to Generate Effective Treatments (TARGET) for Osteosarcoma|
|Principal investigator||Ching C. Lau, MD, PhD|
|Description||OBJECTIVES: - To comprehensively detect genomic, epigenomic, and transcriptomic aberrations in tissue samples from patients with osteosarcoma that may play a role in chemoresistance and metastasis using high-resolution genome-wide technologies. - To identify recurrent genetic mutations involved in the pathogenesis of osteosarcoma, especially for the development of chemoresistance and metastatic tumors. - To identify and validate these biomarkers for new therapeutic targets for patients with osteosarcoma, especially those with metastatic disease and whose tumors are resistant to standard chemotherapy. OUTLINE: This is a multicenter study. Archived tumor tissue and peripheral blood DNA specimens are analyzed for DNA copy number profiling, gene expression profiling, DNA methylation profiling, microRNA profiling, and genomic resequencing. Clinical data including demographics; date of diagnosis, surgery, chemotherapy, recurrence, progression, and death; imaging; toxicity; and pathologic data elements associated with the specimens are also collected and analyzed.|
Call for more information